Date

Tuesday, November 9th 2021

Price

€0 for non-members

€0 for members

Language

English

Organised by

GSK

Categories

Tags

This unique and free networking opportunity allows you to interact with field experts from academia and GSK. We aim to stimulate the exchange of views on the latest advances in vaccine science and immunology in a friendly and inspiring environment.

The agenda includes:

  • 09.15 – 09.30. INTRODUCTION AND WELCOME by Jamila Louahed and
    Yannick Vanloubbeeck

  • 09.30 – 11.00. PLENARY: Profiling the Immune system in health and disease

    • Dieter Lambrechts, KU Leuven | VIB: "Deep-immune profiling of breast cancer tumors treated with checkpoint immunotherapy and bronchoalveolar lavages from COVID-19 patients"

    • Rab Prinjha, Head of Immunology, GSK (TBC)

  • 11.00 – 11.15. BREAK (refreshments served in Arc Foyer)

  • 11.15 – 13.00. UNIVERSITY ELEVATOR PITCHES

  • 13.00 – 14.30. LUNCH (networking)
    14.30 – 15.15. PLENARY: Collaborations & Partnerships Accelerating Vaccine Development

    • Philippe Denoel, GSK: “Partnering with GSK to design & develop vaccine solutions for the future”

    • Yannick Vanloubbeeck, GSK: “Recent partnerships to accelerate vaccine development and manufacture”

    • Rui Portela, GSK | ULB Post Doc: “Multi omic characterisation of vaccine production bioprocesses”

  • 15.15 – 15.45. PLENARY: Young persons’ perspectives of research at GSK

    • Simon Delandre, GSK: “Immunosenescence identification of aging-related biomarkers and association with immune responses to adjuvanted or non-adjuvanted vaccine formulations”

    • George Elias, GSK: “DNA-barcoded dextramers in T-cell antigen discovery and vaccine development"

    • 15.45 – 16.00. Announcement of the 2 winning University Elevator Pitches

    • 16.00 – 16.15. CLOSING REMARKS by Jamila Louahed and Yannick Vanloubbeeck

    • 16.15 – 17.30. DRINK in the Arc Foyer

If you have a promising project and/or idea related to one of the themes listed below and you would like to make a University Elevator Pitch, you are invited to complete the structured template and submit a 250 word abstract by 15 October (postponed due date) to katrien.lorre@flanders.bio, fran.vanheuverswyn@flandersvaccine.be or joelle.gahimbare@biowin.org.

Important: As this is a non-confidential discussion forum to share scientific views, any information presented or otherwise disclosed by participants and/or exchanged during this event is also considered non-confidential and will therefore not be subject to any confidentiality obligations.  

GSK will select abstracts to be presented by the author in the University Elevator Pitch session based on 3 criteria:

  1. Novelty - the abstract should explain “what GSK does not know about your project”

  2. Scientific excellence & innovation

  3. Alignment with themes pre-defined by GSK

You will be informed by 21 October whether or not you have been selected to make a University Pitch. If your abstract is selected, you will be asked to prepare a short presentation (NON-CONFIDENTIAL INFORMATION ONLY – see above).

On the day of the event, representatives of BioWin, flanders.bio and Flanders Vaccine will consider all pitches, irrespective of the theme, and award the best pitches with a prize.

Participation in this event is free, but on invitation only.

This event is supported by BioWin, flanders.bio and Flanders Vaccine. The format will be physical. Please be aware that, in light of the COVID-19 pandemic, you will need to follow the organiser’s safety policies, as well as local laws and restrictions.

Themes for University Elevator Pitches

Immunology and vaccinology

  • Characterisation of host-pathogen interactions or immune responses

  • Research on novel associations between viral/bacterial agents and chronic diseases

  • Immunotherapy of chronic diseases

  • Epigenetic research on modification of innate immune cells (trained immunity)

New vaccine targets and antigen design

  • New tools to refine or accelerate future vaccine target identification (infectious and chronic diseases)

  • Structural vaccinology research

  • Nanoparticles, virus-like particles…

Vaccine delivery

  • Delivery methods/devices related to alternative routes of administration (oral, mucosal, intradermal…)

New technology platforms

  • New immunomodulation technologies and adjuvants

  • Vaccine stability technologies

  • mRNA vaccine technologies

  • Vector technologies (viral, bacterial…)

  • Induction of more efficient and rapid immune responses (1 dose vaccine)

  • Microbiome functions/interventions research

  • Discovery, identification, engineering of human monoclonal antibodies

New technologies to accelerate R&D

  • Assays on a chip for clinical read-outs or quality control and assurance

  • Novel clinical trial designs (incl. human challenge models)

  • Biomarkers research and application of systems biology to new readouts

  • Development of in vitro models such as organoids or organ-on-chip systems

New production process technologies

  • New technologies to characterize or improve biologicals manufacturing (PAT, biosensors, microfluidics, continuous manufacturing…)

Artificial intelligence and digital data analytics

  • Novel applications of systems biology, data modelling/analysis and artificial intelligence